5 studies found for:    17452677 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Terminated Perioperative Treatment With Zoledronic Acid in Patients With Resectable Pancreas Cancer
Condition: Adenocarcinoma
Intervention: Drug: Zoledronic acid
2 Completed OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.
Condition: Pancreatic Cancer
Intervention: Drug: Tarceva (erlotinib HCl, OSI-774)
3 Terminated Lag-3 and Gemcitabine for Treatment of Advanced Pancreas Cancer
Condition: Pancreatic Neoplasms
Interventions: Drug: Gemcitabine;   Biological: LAG-3
4 Recruiting Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer
Conditions: Pancreatic Neoplasms;   Pancreatic Cancer;   Cancer of Pancreas
Interventions: Drug: MEDI4736;   Drug: Tremelimumab;   Radiation: Sterostatic body radiation Cohort A1: 1 dose therapy (SBRT)
5 Completed Gemcitabine With or Without Erlotinib in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Drug: erlotinib hydrochloride;   Drug: gemcitabine hydrochloride

Indicates status has not been verified in more than two years